X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs VENUS REMEDIES - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES VENUS REMEDIES PIRAMAL ENTERPRISES/
VENUS REMEDIES
 
P/E (TTM) x 11.1 -4.8 - View Chart
P/BV x 1.9 0.2 1,080.8% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 PIRAMAL ENTERPRISES   VENUS REMEDIES
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
VENUS REMEDIES
Mar-18
PIRAMAL ENTERPRISES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs3,083126 2,448.8%   
Low Rs1,90261 3,112.9%   
Sales per share (Unadj.) Rs589.7301.8 195.4%  
Earnings per share (Unadj.) Rs284.0-24.9 -1,142.1%  
Cash flow per share (Unadj.) Rs310.52.5 12,202.9%  
Dividends per share (Unadj.) Rs25.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs1,467.0293.3 500.2%  
Shares outstanding (eoy) m180.2712.34 1,460.9%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x4.20.3 1,364.2%   
Avg P/E ratio x8.8-3.8 -233.4%  
P/CF ratio (eoy) x8.036.7 21.8%  
Price / Book Value ratio x1.70.3 533.0%  
Dividend payout %8.80-   
Avg Mkt Cap Rs m449,3321,154 38,944.0%   
No. of employees `0006.80.9 739.8%   
Total wages/salary Rs m19,881393 5,057.6%   
Avg. sales/employee Rs Th15,535.64,026.1 385.9%   
Avg. wages/employee Rs Th2,905.4425.0 683.7%   
Avg. net profit/employee Rs Th7,482.5-331.8 -2,255.2%   
INCOME DATA
Net Sales Rs m106,3103,724 2,854.7%  
Other income Rs m2,59523 11,534.7%   
Total revenues Rs m108,9063,747 2,906.8%   
Gross profit Rs m51,599395 13,069.6%  
Depreciation Rs m4,773338 1,411.0%   
Interest Rs m29,783354 8,406.2%   
Profit before tax Rs m19,638-275 -7,133.2%   
Minority Interest Rs m2,8010-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-28,76432 -91,025.9%   
Profit after tax Rs m51,203-307 -16,683.9%  
Gross profit margin %48.510.6 457.8%  
Effective tax rate %-146.5-11.5 1,276.1%   
Net profit margin %48.2-8.2 -584.4%  
BALANCE SHEET DATA
Current assets Rs m118,1542,638 4,479.5%   
Current liabilities Rs m462,2602,305 20,057.7%   
Net working cap to sales %-323.78.9 -3,619.5%  
Current ratio x0.31.1 22.3%  
Inventory Days Days27135 19.6%  
Debtors Days Days4746 100.4%  
Net fixed assets Rs m113,7274,871 2,334.9%   
Share capital Rs m361123 292.1%   
"Free" reserves Rs m264,0933,496 7,554.9%   
Net worth Rs m264,4543,619 7,307.2%   
Long term debt Rs m242,2061,374 17,622.7%   
Total assets Rs m726,8347,509 9,680.1%  
Interest coverage x1.70.2 744.2%   
Debt to equity ratio x0.90.4 241.2%  
Sales to assets ratio x0.10.5 29.5%   
Return on assets %11.10.6 1,765.0%  
Return on equity %19.4-8.5 -228.3%  
Return on capital %10.31.6 651.5%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m15,1100-   
Fx outflow Rs m4,298517 832.0%   
Net fx Rs m10,813-517 -2,093.4%   
CASH FLOW
From Operations Rs m-159,666514 -31,039.2%  
From Investments Rs m-17,677-123 14,360.1%  
From Financial Activity Rs m186,503-387 -48,179.4%  
Net Cashflow Rs m9,3644 222,959.5%  

Share Holding

Indian Promoters % 52.9 32.9 161.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 0.2 2,222.2%  
FIIs % 26.6 0.6 4,586.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 66.4 24.8%  
Shareholders   93,274 20,121 463.6%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 18, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS